Is serum level of nestin useful in detecting epithelial ovarian cancer?

Sal, Veysel; Kahramanoğlu, İlker; Beşe, Tugan; Demirkıran, Fuat; Sofiyeva, Nigar; Soyman, Zeynep; Durmuş, Sinem; Gelışgen, Remise; Arvas, Macit; Uzun, Hafize

doi:10.1111/jog.13220

Cited by 4 publications

(4 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Immunohistochemical results of their study revealed nestin expression was not present in benign masses and gradually increased from early borderline to advanced malignant ovarian tumors. These authors have concluded that nestin overexpression was associated with more advanced stage and higher histological grade of serous adenocarcinoma cases [21]. Zhang et al [22] have suggested that nestin may be significantly associated with the resistance to chemotherapy as in their study the expression of nestin in chemoresistant cells was much higher when compared to parental hepatocellular cancer cells.…”

Section: Discussionmentioning

confidence: 95%

“…He et al [9] have studied nestin expression evaluated with the use of immunohistochemistry (IHC) in 315 cases of various clinical and histological stages of epithelial ovarian neoplasms as well as in 52 control cases of normal ovarian epithelia. Sal et al [21] have found increased concentrations of soluble nestin in the serum of ovarian cancer patients. Immunohistochemical results of their study revealed nestin expression was not present in benign masses and gradually increased from early borderline to advanced malignant ovarian tumors.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Prognostic significance of TEM7 and nestin expression in women with advanced high grade serous ovarian cancer

et al. 2018

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 95%

Section: Discussionmentioning

confidence: 99%

Prognostic significance of TEM7 and nestin expression in women with advanced high grade serous ovarian cancer

et al. 2018

View full text Add to dashboard Cite

show abstract

“…There are still limited data investigating serum markers to differentiate between benign and malignant ovarian tumors ( 27 ) . For long time, the best documented and the most frequently recommended serum marker has been CA-125 in the management of adnexal masses ( 28 ) .…”

Section: Discussionmentioning

confidence: 99%

YKL-40 in the diagnosis, prediction of prognosis, and platinum sensitivity in serous epithelial ovarian cancer

Kahramanoğlu¹,

Tokgözoğlu²,

Turan³

et al. 2018

tjod

Self Cite

View full text Add to dashboard Cite

Objective:To evaluate the use of YKL-40 in the discrimination between benign and malignant adnexal mass and to determine its prognostic value in assessing residual tumor after primary cytoreduction and platinum sensitivity in serous epithelial ovarian carcinoma (EOC). Materials and Methods:During the three years from January 2015 to December 2017, a nonconsecutive series of 100 patient (60 malignant, 40 benign) who underwent surgery for an adnexal mass were enrolled in the study. Preoperatively, serum samples were collected for YKL-40 level analysis.Results:YKL-40 [receiver operator characteristics (ROC)-area under curve (AUC)=0.83] was a significantly better predictor of EOC than cancer antigen-125 (ROC-AUC=0.75). Using a cut-off for YKL-40 of 47.7 ng/mL had a sensitivity of 80% and a specificity of 70%. Higher serum YKL-40 levels were associated with advanced stage, higher grade, residual tumor after primary cytoreduction and recurrence. Platinum-sensitive patients had significantly elevated levels of YKL-40 compared with platinum-resistant or refractory patients.Conclusion:The results obtained from our study support the use of serum YKL-40 for the discrimination between malignant and benign ovarian tumors. YKL-40 levels in patients with serous EOC may also predict disease residual disease after primary cytoreduction and recurrence. Further studies are needed to understand the relationship between YKL-40 and platinum sensitivity.

show abstract

“…Furthermore, a correlation has been demonstrated between nestin expression and the stage of cancer, lymph node involvement and distant metastases [37]. It was also found that an increased expression of serum nestin in patients with ovarian cancer correlated with a more aggressive course of the disease [38]. An increased expression of nestin in breast cancer cells was shown to be a negative prognostic factor and was associated with the patient's younger age, a higher grade, nodal involvement and shorter survival [21,39,40].…”

Section: Nestin As a Marker Of Cancer Stem Cellsmentioning

confidence: 95%

Emerging biomarker in carcinogenesis. Focus on Nestin

Nowogrodzka¹,

Jankowska‐Konsur²

2022

pdia

View full text Add to dashboard Cite

Nestin is a protein belonging to class VI intermediate filaments, which is involved in organogenesis, cellular metabolism and cytoskeletal organisation. Originally found to be expressed in neuroepithelial stem cells, nestin is also expressed in other tissues. It plays an important role in the carcinogenesis and angiogenesis. Its increased expression in melanoma is associated with an aggressive course of the disease and poor prognosis. Research findings for nonmelanocytic skin neoplasms are inconclusive. The aim of this paper was to systematize knowledge on the role of nestin in cancerogenesis. The authors focused in particular on the expression of nestin in skin malignancies, as well as on the potential role of nestin in the pathogenesis, prognosis and treatment of cutaneous neoplasms.

show abstract

Is serum level of nestin useful in detecting epithelial ovarian cancer?

Cited by 4 publications

References 24 publications

Prognostic significance of TEM7 and nestin expression in women with advanced high grade serous ovarian cancer

Prognostic significance of TEM7 and nestin expression in women with advanced high grade serous ovarian cancer

YKL-40 in the diagnosis, prediction of prognosis, and platinum sensitivity in serous epithelial ovarian cancer

Emerging biomarker in carcinogenesis. Focus on Nestin

Contact Info

Product

Resources

About